| abstract |
The invention generally provides a method for monitoring, diagnosing, forecasting, and treating glioma. Specifically, the invention provides three (3) glioma prognosis subclasses, which are differentially associated with activation of the akt and notch signaling pathways. Tumor that exhibits PN neural or proneural lineage markers (including notch path elements) shows longer median patient survival, while the two remaining tumor markers Prolif and Month are associated with a clipped survival. Tumors classified in this way can also be treated with the appropriate therapeutic agent -PN, -Prolif or -Mes corresponding to the sub-classification in combination with antimitotic agents, antiangiogenic agents, Akt antagonists, and neural differentiation agents. Alternatively, the invention also provides a method of prognosis or diagnosis of glioma with a two-gene model based on the expression levels of PTEN and DLL3. |